Capricor Therapeutics to Participate in Upcoming Conferences
October 22, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
Presentations to Focus on Company’s Exosome-based and Duchenne Muscular Dystrophy Therapies LOS ANGELES, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Linda Marbán, Ph.D, CEO of Capricor Therapeutics, Inc....
Capricor Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
October 03, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LA JOLLA, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) will provide a presentation at the 2018 Cell & Gene Meeting on the Mesa today on its cell therapy,...
Capricor Therapeutics Presents Results of Studies of CAP-2003 at Gordon Research Conference on Extracellular Vesicles
August 21, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Aug. 21, 2018 (GLOBE NEWSWIRE) -- At the Gordon Research Conference on Extracellular Vesicles in Newry, Maine, Capricor Therapeutics (NASDAQ: CAPR) presented research findings on the...
Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 09, 2018 16:00 ET
|
Capricor Therapeutics, Inc.
To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology...
FibroGen Reports Second Quarter 2018 Financial Results
August 07, 2018 16:02 ET
|
FibroGen, Inc
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic...
Capricor Therapeutics and PPMD to Host Webinar for Duchenne Muscular Dystrophy Community on July 18
July 13, 2018 09:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, July 13, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) and Parent Project Muscular Dystrophy (PPMD) will host a webinar at 1 p.m. ET on July 18 to provide information...
Capricor Therapeutics to Present at PPMD Annual Conference
June 28, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, June 28, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics’ (NASDAQ:CAPR) chief medical officer, Deborah Ascheim, M.D., will present a corporate overview at the Parents Project Muscular...
Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint
June 27, 2018 07:00 ET
|
Summit Therapeutics plc
Ezutromid Development to be DiscontinuedSummit to Focus on Advancing its Pipeline of New Mechanism AntibioticsConference Call Scheduled for 8:00am EDT / 1:00pm BST OXFORD, United Kingdom and...
Capricor Therapeutics to Present at the 2018 BIO International Convention in Boston
May 29, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 29, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare disorders,...
Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 10, 2018 16:00 ET
|
Capricor Therapeutics, Inc.
HOPE-2 Clinical Trial is Currently Enrolling Patients Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, May 10, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a...